Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24999716 | 0.99 | CA12 (0.44) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24306666 | 0.99 | CA12 (0.44) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24306672 | 0.97 | CA12 (0.48) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24307846 | 0.97 | CA12 (0.48) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24999238 | 0.96 | CA12 (0.47) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24999619 | 0.96 | CA12 (0.47) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24999242 | 0.96 | CA12 (0.47) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24306667 | 0.96 | CA12 (0.46) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24999710 | 0.96 | CA12 (0.46) | CA12CA1CA2CA9MCL1 | |
| SCHEMBL24307851 | 0.96 | CA12 (0.46) | CA12CA1CA2CA9MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230200222-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230200222-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11678569-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11678569-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230200222-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | PIEZO1, LEF1, L1CAM | CA12 1391/4885CA1 1719/4885CA2 2579/4885 |
| US-11678569-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | PIEZO1, LEF1, L1CAM | CA12 1391/4885CA1 1719/4885CA2 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.